key: cord-0800948-nywikymb authors: Heneghan, C.; Brassey, J.; Jefferson, T. title: The Impact of COVID-19 Restrictions on Childhood Vaccination Uptake: A Rapid Review date: 2021-06-30 journal: nan DOI: 10.1101/2021.06.25.21259371 sha: 12b911c2722bf9a2372ddc273b05e1be8a1a3051 doc_id: 800948 cord_uid: nywikymb Abstract: Background Vaccines are highly effective for preventing a range of childhood infections. However, there have been concerns about an alarming decline in vaccinations in 2020 due to the COVID-19 pandemic. Methods We performed a rapid review for studies that assessed childhood vaccination uptake during restrictive phases of the covid-19 pandemic. Results We found 35 published studies that compared changes in the pattern of childhood vaccinations before and during the pandemic. Thirteen were surveys; two mixed-methods surveys and interviews, three modelling studies and 17 retrospective cohort studies with historical controls. We also included ten reports by national or international agencies that had original data on vaccination uptake. Significant global disruptions to vaccine services were reported in Africa, Asia, America (including Latin America and the Caribbean) and Europe. We also found evidence of significant disruption to vaccine uptake for diphtheria tetanus pertussis, BCG, measles and polio. Countries, where vaccination rates were already suboptimal, had greater drops in uptake and there was evidence of smaller declines in younger children compared to older children. Children born to women who could not read and write were more likely to have an incompletely immunized child. Various initiatives were used to drive up vaccination rates post restrictions. Conclusions Obstacles to the delivery of vaccination services during the COVID-19 pandemic drove down immunisation rates, especially in disadvantaged people and poorer countries. Vaccines have proven to be highly effective at preventing disease and deaths associated with a range of childhood infections. Many childhood diseases that used to be common, including diphtheria, measles, mumps, rubella, pertussis, polio and tetanus, can be prevented by vaccination. The distribution and uptake of vaccines has improved across the globe. In 2019, 86% of infants worldwide received three doses of diphtheria, tetanus, pertussis (DTP3) vaccines, and childhood immunisation is estimated to prevent 2 to 3 million annual deaths from infectious diseases. [1] Despite their effectiveness, the WHO and UNICEF warned of an 'alarming decline' in vaccinations in 2020 due to the COVID-19 pandemic. Data from the first four months highlighted a substantial drop in the number of children completing three doses of the DTP3 vaccine -the first time in 28 years global reductions were seen. [2] UNICEF regards protection from vaccinepreventable diseases as a child's fundamental right and states that right now is 'time to vigorously monitor the impact on immunisation and plan for services that reach the most vulnerable once restrictions are lifted.' [3] We, therefore, set out to synthesise the published literature on the impact of the COVID-19 pandemic restrictions on vaccination coverage for children. We performed a rapid review using a flexible framework for restricted systematic reviews. [4] For the initial search, we restricted the results to peerreviewed articles using the LitCovid database. LitCovid is a curated literature hub for tracking upto-date scientific information about SARS-CoV-2 (https://www.ncbi.nlm.nih.gov/research/coronaviru s/). It is a comprehensive resource on the subject, providing central access to relevant articles in PubMed. We searched for various terms/phrases associated with childhood vaccinations, e.g., 'vaccines', 'vaccination' or 'immunisation' and 'children' or 'infants'. We screened the title and abstract for inclusion and extracted data into templates on the study identifier, country, the type of vaccination, the study type, the age of the included populations, the primary methods and the main results. We did not formally assess quality as studies were retrospective reviews of records that involved an active lockdown phase and a historical control period, surveys or modelling studies. The quality of included studies was instead assessed using an adapted version of the Oxford Centre for Evidence-Based Medicine Levels of Evidence (https://www.cebm.ox.ac.uk/resources/levels-ofevidence/ocebm-levels-of-evidence) We also included reports by national or international agencies that included original data on vaccination uptake. We summarised data narratively and reported the outcomes as stated, including quantitative estimates, where feasible and relevant. We presented the data by disruption of services and by diphtheria tetanus pertussis, BCG, measles and polio vaccine uptake. We also extracted up to date numbers from the Global Polio Eradication Initiative (GPEI) database to assess the latest impact of polio vaccination disruptions in Afghanistan and Pakistan, where polio is endemic (https://polioeradication.org/). Our review process, strategy and rationale can be accessed at https://collateralglobal.org/article/what-is-a-rapidreview/. Figure 1 reports the Identification of Childhood Vaccination studies via databases. From 389 records identified, we found 35 published studies that compared changes in the pattern of childhood vaccinations before and during the pandemic. 32 studies assessed evidence from 22 countries: Afghanistan, Bangladesh, China, Germany, India, Indonesia, Japan, Kuwait, The Netherlands, Portugal, Rwanda, Scotland, Senegal, Sierra Leone, South Korea, Spain (16 countries, one study each); England, Ethiopia, Italy, Pakistan, Saudi Arabia (five countries, two studies each). For the USA, there were six studies. Three studies reported on multiple countries: two were done in Africa [Masresha 2020 and Abbas K 2020] and one in South-East Asia and the Western Pacific (SEAR/WPR) [Harris 2021 ]. In terms of methods, thirteen studies were surveys; two were mixed-methods surveys and interviews, three studies were models (one provided data on a retrospective cohort), and 17 were retrospective cohort studies. We also included ten reports by national or international agencies that had original data on vaccination uptake: one each for Blue Cross, the Nuffield Trust, PAHO and Public Health England, two reports for UNICEF (one jointly with PAHO) and four WHO reports. (See TABLE 2) Disruption to services Data collated by the WHO, UNICEF, Gavi, and the Sabin Vaccine Institute show that pandemic restrictions substantially reduced the delivery of immunization services in at least 68 countries affecting over 80 million children under the age of one. [UNICEF 2020] According to the WHO's first pulse interim survey published in August 2020, 16/91 (18%) of countries reported severe/complete disruption of routine mobile immunization services, and 10% reported disruption to static routine immunisation services. About half of the countries reported partial disruptions of routine immunisation for both health facilities and mobile services. [WHO first-round survey 2020] On May 15, the pulse survey reported that more than half (53%) of the 129 countries with available data had moderate-tosevere disruptions or a total suspension of vaccination services from March to April 2020. [ We reviewed the latest Afghanistan data from GPEI (https://polioeradication.org/). As of 16 June, one case of wild poliovirus type 1 (WPV1) has been reported for 2021 and a total of 56 cases in 2020. [6] The latest status for Afghanistan suggests that the country remains affected by WPV1 and circulating vaccine-derived poliovirus type 2 (cVDPV2). In March 2021, 6.6 million children were vaccinated against polio during the National Immunisation Days. [7] There were forty cases of circulating cVDPV2 reported in 2021 and 308 cases in 2020. An In April 2020, The WHO reported that Niger had an outbreak of vaccine-derived poliovirus that affected two children-having suspended the vaccination campaign due to the pandemic. Niger's last wild polio case was in 2012 [9] . Niger joins 15 countries experiencing vaccinederived poliovirus outbreaks in Africa. No wild poliovirus has been detected in Africa since 2016. Niger joins the list of countries experiencing vaccine-derived poliovirus outbreaks in Africa. The . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 30, 2021. The evidence in this review comes from a wide range of conditions and countries that highlight significant disruptions to childhood vaccine services. We found reductions in diphtheria tetanus pertussis, BCG, measles and polio vaccine uptake, as well as a range of other vaccines regularly given to children. Reductions in many settings were reversed once restrictions were lifted. However, not all settings reported a return to complete normality. Smaller declines were seen in younger children than older children. In addition, children born to women who could not read and write were more likely to be incompletely immunised. Barriers to access and maintaining public transport infrastructure impacted uptake of childhood vaccinations as well. The true impact of COVID-19 disruptions on childhood vaccination services is yet to be determined. Two years after reductions in measles vaccination during the Ebola outbreak in Guinea, the incidence of measles increased from 2.7 per million in 2015 to 11.5 per million in 2016 and 52.5 per million in 2017, of which 65% of cases were confirmed in those aged < 5 years. [10] Worldwide measles deaths climbed by 50% from 2016 to 2019, with over 200,000 lives lost in 2019. [11] Low levels of polio vaccination and a lack of immunity can leave countries at risk of polio returning. Indonesia, Mozambique, Myanmar, Papua New Guinea, and the Philippines are currently considered key-at-risk countries by GPEI, Afghanistan, and Pakistan affected by ongoing endemic WPV1 and cVDPV2. [11] There is a concerted effort underway to eradicate polio. The GPEI reports fewer cases in 2021 compared to the same period last year. This is promising, despite the lockdowns; however, the potential for underreporting exists due to the pandemic. The effects of Polio can be devastating: in 1996, wild poliovirus paralysed more than 75,000 children in Africa. [12] Therefore, maintaining sustained vaccination levels and disease surveillance remains a priority for at-risk countries. Furthermore, several barriers were reported to vaccination, including a lack of clarity around whether vaccination services were operating, as usual, difficulties in organising vaccination appointments, and fears around contracting COVID-19. [Bell S 2020] We did not formally assess the quality of the included studies. However, clinical audit and service evaluation remain valuable for analysing and targeting improvements in healthcare. Publication bias will favour studies that highlight disruptions and account for excess reporting of decreases in vaccination levels. However, alongside those studies, reviews by international bodies highlight consistent drops in vaccination uptakes during the restrictive phases of the pandemic. Studies that report no reductions in vaccination are essential; they highlight strategies that can overcome disruptions during restrictions and -crucially -after they have been lifted. Reports of vaccine coverage may not be 100% accurate, particularly during periods of upheaval such as in a pandemic. COVID-19 pandemic measures caused significant disruption to childhood vaccination services and uptake. In future pandemics, and for the remainder of the current one, policymakers must ensure access to vaccination services and provide catchup programs to maintain high levels of immunisation, especially in those most vulnerable to childhood diseases in order to avoid further inequalities. This review received funding from Collateral Global. In addition, CH receives funding support from the NIHR SPCR. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Research Working Group, for which he receives no funds. TJ is funded to co-author rapid reviews on the impact of Covid restrictions by the Collateral Global Organisation. CJH holds grant funding from the NIHR, the NIHR School of Primary Care Research, the NIHR BRC Oxford and the World Health Organization for a series of Living rapid review on the modes of transmission of SARs-CoV-2 reference WHO registration No2020/1077093. He has received financial remuneration from an asbestos case and given legal advice on mesh and hormone pregnancy tests cases. He has received expenses and fees for his media work, including occasional payments from BBC Radio 4 Inside Health and The Spectator. He receives expenses for teaching EBM and is also paid for his GP work in NHS out of hours (contract Oxford Health NHS Foundation Trust). He has also received income from the publication of a series of toolkit books and appraising treatment recommendations in non-NHS settings. He is the Director of CEBM and is an NIHR Senior Investigator. He is co-director of the Global Centre for healthcare and Urbanisation based at Kellogg College at Oxford, and he is a scientific advisor to Collateral Global. JB is a major shareholder in the Trip Database search engine (www.tripdatabase.com) and an employee. In relation to this work, Trip has worked with many organisations over the years; none have any links with this work. Their main current projects are with AXA and Collateral Global. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 30, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 30, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 30, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 30, 2021. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 30, 2021. https://www.who.int/news/item/22-05-2020-at-least-80million-children-under-one-at-risk-of-diseases-such-asdiphtheria-measles-and-polio-as-covid-19-disruptsroutine-vaccination-efforts-warn-gavi-who-and-unicef WHO Niger 2020 Niger reports a new polio outbreak. Niger has reported a new polio outbreak that has affected two children in Niamey and Tillaberi region, https://www.afro.who.int/news/niger-reports-new-poliooutbreak. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 Selection process 8 Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. 1 Data collection process 9 Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 28 characteristics and comparing against the planned groups for each synthesis (item #5)). 13b Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. 1 13c Describe any methods used to tabulate or visually display results of individual studies and syntheses. 1 13d Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. N/A 13e Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). 13f Describe any sensitivity analyses conducted to assess robustness of the synthesized results. Reporting bias assessment 14 Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). Certainty assessment 15 Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. 16a Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. 16b Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 23c Discuss any limitations of the review processes used. 6 23d Discuss implications of the results for practice, policy, and future research. Registration and protocol 24a Provide registration information for the review, including register name and registration number, or state that the review was not registered. N/A 24b Indicate where the review protocol can be accessed, or state that a protocol was not prepared. 1 24c Describe and explain any amendments to information provided at registration or in the protocol. 1 Support 25 Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. Competing interests 26 Declare any competing interests of review authors. 7 Availability of data, code and other materials 27 Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. For more information, visit: http://www.prisma-statement.org/ . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 30, 2021. ; https://doi.org/10.1101/2021.06.25.21259371 doi: medRxiv preprint Redefining rapid reviews: a flexible framework for restricted systematic reviews The impact of a prolonged ebola outbreak on measles elimination activities in Guinea The authors would like to thank Martin Kulldorff and AJ Kay for comments on the draft. No approval was necessary. All data included in the review is provided in the tables and text.